vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Perella Weinberg Partners is the larger business by last-quarter revenue ($219.2M vs $205.4M, roughly 1.1× COLLEGIUM PHARMACEUTICAL, INC). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 6.3%, a 2.0% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs -2.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $30.5M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
COLL vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $219.2M |
| Net Profit | $17.0M | $13.8M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | 8.5% |
| Net Margin | 8.3% | 6.3% |
| Revenue YoY | 12.9% | -2.9% |
| Net Profit YoY | 35.3% | — |
| EPS (diluted) | $0.48 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $219.2M | ||
| Q3 25 | $209.4M | $164.6M | ||
| Q2 25 | $188.0M | $155.3M | ||
| Q1 25 | $177.8M | $211.8M | ||
| Q4 24 | $181.9M | $225.7M | ||
| Q3 24 | $159.3M | $278.2M | ||
| Q2 24 | $145.3M | $272.0M | ||
| Q1 24 | $144.9M | $102.1M |
| Q4 25 | $17.0M | $13.8M | ||
| Q3 25 | $31.5M | $6.0M | ||
| Q2 25 | $12.0M | $2.7M | ||
| Q1 25 | $2.4M | $17.3M | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $9.3M | $16.4M | ||
| Q2 24 | $19.6M | $-66.0M | ||
| Q1 24 | $27.7M | $-35.8M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | 8.5% | ||
| Q3 25 | 29.7% | 5.4% | ||
| Q2 25 | 18.7% | 5.8% | ||
| Q1 25 | 12.2% | 5.5% | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 21.9% | 12.9% | ||
| Q2 24 | 32.7% | -30.2% | ||
| Q1 24 | 34.1% | -52.4% |
| Q4 25 | 8.3% | 6.3% | ||
| Q3 25 | 15.0% | 3.6% | ||
| Q2 25 | 6.4% | 1.8% | ||
| Q1 25 | 1.4% | 8.2% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.9% | 5.9% | ||
| Q2 24 | 13.5% | -24.3% | ||
| Q1 24 | 19.1% | -35.1% |
| Q4 25 | $0.48 | $0.11 | ||
| Q3 25 | $0.84 | $0.08 | ||
| Q2 25 | $0.34 | $0.04 | ||
| Q1 25 | $0.07 | $0.24 | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.27 | $0.24 | ||
| Q2 24 | $0.52 | $-1.21 | ||
| Q1 24 | $0.71 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $255.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $-127.4M |
| Total Assets | $1.7B | $797.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $255.9M | ||
| Q3 25 | $285.9M | $185.5M | ||
| Q2 25 | $222.2M | $145.0M | ||
| Q1 25 | $197.8M | $111.2M | ||
| Q4 24 | $162.8M | $407.4M | ||
| Q3 24 | $120.0M | $335.1M | ||
| Q2 24 | $271.6M | $185.3M | ||
| Q1 24 | $318.0M | $156.7M |
| Q4 25 | $301.7M | $-127.4M | ||
| Q3 25 | $274.8M | $-302.4M | ||
| Q2 25 | $232.2M | $-318.4M | ||
| Q1 25 | $234.4M | $-323.1M | ||
| Q4 24 | $228.8M | $-421.4M | ||
| Q3 24 | $234.3M | $-360.8M | ||
| Q2 24 | $216.6M | $-283.0M | ||
| Q1 24 | $222.2M | $161.9M |
| Q4 25 | $1.7B | $797.6M | ||
| Q3 25 | $1.6B | $650.2M | ||
| Q2 25 | $1.6B | $606.7M | ||
| Q1 25 | $1.6B | $570.5M | ||
| Q4 24 | $1.7B | $876.8M | ||
| Q3 24 | $1.6B | $810.9M | ||
| Q2 24 | $1.1B | $645.5M | ||
| Q1 24 | $1.1B | $583.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $34.8M |
| Free Cash FlowOCF − Capex | $122.4M | $30.5M |
| FCF MarginFCF / Revenue | 59.6% | 13.9% |
| Capex IntensityCapex / Revenue | 0.3% | 2.0% |
| Cash ConversionOCF / Net Profit | 7.25× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $34.8M | ||
| Q3 25 | $78.4M | $59.2M | ||
| Q2 25 | $72.4M | $56.1M | ||
| Q1 25 | $55.4M | $-176.5M | ||
| Q4 24 | $84.6M | $223.4M | ||
| Q3 24 | $-9.0M | $200.3M | ||
| Q2 24 | $67.4M | $90.0M | ||
| Q1 24 | $61.9M | $-206.3M |
| Q4 25 | $122.4M | $30.5M | ||
| Q3 25 | $78.3M | $57.6M | ||
| Q2 25 | $72.4M | $55.3M | ||
| Q1 25 | $54.6M | $-177.6M | ||
| Q4 24 | $84.1M | $207.0M | ||
| Q3 24 | $-9.2M | $199.3M | ||
| Q2 24 | $67.1M | $83.7M | ||
| Q1 24 | $61.4M | $-214.8M |
| Q4 25 | 59.6% | 13.9% | ||
| Q3 25 | 37.4% | 35.0% | ||
| Q2 25 | 38.5% | 35.6% | ||
| Q1 25 | 30.7% | -83.8% | ||
| Q4 24 | 46.2% | 91.7% | ||
| Q3 24 | -5.8% | 71.6% | ||
| Q2 24 | 46.2% | 30.8% | ||
| Q1 24 | 42.3% | -210.3% |
| Q4 25 | 0.3% | 2.0% | ||
| Q3 25 | 0.1% | 0.9% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.4% | 0.5% | ||
| Q4 24 | 0.3% | 7.3% | ||
| Q3 24 | 0.2% | 0.4% | ||
| Q2 24 | 0.2% | 2.3% | ||
| Q1 24 | 0.4% | 8.3% |
| Q4 25 | 7.25× | 2.52× | ||
| Q3 25 | 2.49× | 9.85× | ||
| Q2 25 | 6.05× | 20.50× | ||
| Q1 25 | 22.92× | -10.18× | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | 12.23× | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
